No 'wearing-off effect' seen with fremanezumab in the real-world: a retrospective, claims-based analysis of migraine-related healthcare resource and acute medication use

被引：0
|
作者：
Ailani, J. [1 ]
Xie, H. [2 ]
Driessen, M. [3 ]
Ortega, M. [4 ]
Wang, Y. [2 ]
Ramirez, Campos, V [2 ]
Lim, S. [2 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[3] Teva Pharmaceut Ind Ltd, Amsterdam, Netherlands
[4] Teva Pharmaceut, Parsippany, NJ USA
来源：
HEADACHE | 2023年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-130
引用
收藏
页码：148 / 148
页数：1
相关论文
共 48 条
  • [1] No 'Wearing-Off Effect' Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use
    Ailani, Jessica
    Xie, Handing
    Driessen, Maurice
    Ortega, Mario
    Wang, Yitong
    Campos, Verena Ramirez
    Lim, Sangtaeck
    NEUROLOGY, 2023, 100 (17)
  • [2] Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants
    Eugeni, P.
    Rooney, M. E.
    Saikali, N. P.
    Niu, Z.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    McVige, J. W.
    HEADACHE, 2022, 62 : 158 - 158
  • [3] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    HEADACHE, 2021, 61 : 71 - 72
  • [4] Real-world Reductions in Migraine-related Healthcare Resource Utilization for German Patients Initiating Fremanezumab
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yilma, B.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 420 - 420
  • [5] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
    Afridi, S.
    Totev, T.
    Krasenbaum, L. J.
    Terasawa, E.
    Akcicek, H.
    Dhiraj, D.
    Sun, R.
    Yilma, B.
    Driessen, M. T.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
    Afridi, Shazia
    Totev, Todor I.
    Krasenbaum, Lynda J.
    Terasawa, Emi
    Akcicek, Hasan
    Dhiraj, Dalbir
    Sun, Rochelle
    Yilma, Binyam
    Driessen, Maurice T.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 74 - 75
  • [7] REAL-WORLD REDUCTIONS IN ACUTE MEDICATION USE FOR PATIENTS WITH MIGRAINE INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Krasenbaum, L. J.
    Driessen, M. T.
    Seminerio, M. J.
    DiEgidio, R.
    Tian, M.
    VALUE IN HEALTH, 2022, 25 (07) : S325 - S325
  • [8] No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study
    Florescu, Anna Maria
    Lannov, Laerke Vig
    Younis, Samaira
    Cullum, Christopher Kjaer
    Chaudhry, Basit Ali
    Do, Thien Phu
    Amin, Faisal Mohammad
    CEPHALALGIA, 2024, 44 (01) : 3331024231222915
  • [9] REAL-WORLD REDUCTIONS IN MIGRAINE-RELATED HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Driessen, M. T.
    Krasenbaum, L. J.
    Ramirez-Campos, V
    DiEgidio, R.
    Tian, M.
    Seminerio, M. J.
    VALUE IN HEALTH, 2022, 25 (07) : S346 - S346
  • [10] Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
    Buse, Dawn C.
    Krasenbaum, Lynda J.
    Seminerio, Michael J.
    Packnett, Elizabeth R.
    Carr, Karen
    Ortega, Mario
    Driessen, Maurice T.
    PAIN AND THERAPY, 2024, 13 (03) : 511 - 532
12345